Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have evolved from glucose-lowering agents to a cornerstone of cardiovascular and chronic kidney disease (CKD) care [1]. This evidence concerns the gene SLC5A2 and chronic kidney disease.